Medical weight loss for men
A blood test before anything is prescribed, a clinician who builds your plan around your markers, and a retest every 6 months to show what’s changing inside.
From £59 / month First month for new customers on a 12-month plan, at the starting dose. Everything included.
- First payment
- from £59
- Then, every 28 days (pens) or 30 (tablets)
- from £129
- 12-month plan payments
- 13 (pens), 12 (tablets)
Subject to clinical approval
Compare the 4 treatment options- Part of the SheMed Group: over 100,000 people supported across the UK
- Blood tests, clinician reviews and support included
- Delivered the next working day, discreetly packaged
Who it’s for
Always a clinical decision, made after your blood test and health review.
May be considered
- Adults with a BMI of 30 or over
- Adults with a BMI of 27 or over alongside a weight-related health condition
Not suitable
- In pregnancy, or when trying to conceive
- Under 18
- With certain medical histories: the clinician screens for these, and the patient information leaflet carries the full list
How it works
Check your eligibility
A short online assessment of your health and history.
Take your blood test
An at-home kit measures your baseline markers.
Reviewed by a clinician
Your clinician builds your care plan around what your results show.
Ongoing care
Monthly delivery, support when you need it, a retest every 6 months.
The treatments, side by side
If treatment is right for you, these are the medicines available through the service. Every price includes the whole programme. Which one suits you is a clinical conversation, not a menu choice.
| WegovyWeekly pen | Wegovy PillDaily tablet | MounjaroWeekly pen | FoundayoDaily tablet | |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide | Orforglipron |
| Form | Pre-filled pen, once a week | Tablet, once a day | Pre-filled pen, once a week | Tablet, once a day |
| Starting dose | 0.25mg | 1.5mg | 2.5mg | 0.8mg |
| From | £59 / month | £69 / month | £154 / month | £64 / month |
| View Wegovy | View Wegovy Pill | View Mounjaro | View Foundayo |
| WegovyWeekly pen | Wegovy PillDaily tablet | MounjaroWeekly pen | FoundayoDaily tablet | |
|---|---|---|---|---|
| Average weight loss in its main trial* | 18.7% (7.2mg, STEP UP, 72 weeks) | 13.6% (25mg, OASIS 4, 64 weeks) | 20.9% (15mg, SURMOUNT-1, 72 weeks) | 11.2% (highest trial dose, ATTAIN-1, 72 weeks) |
*Averages from each medicine's own main trial on its main analysis: separate trials with different designs and durations, not head-to-head comparisons, and not a prediction for any one person. Placebo groups lost 2.1% to 3.9% across these trials. Each medicine's page carries its fuller results and sources.
Lowest prices shown: the first month for new customers on a 12-month plan, at the starting dose. Full dose-by-plan pricing is on each treatment page.
Questions, asked and answered
Which treatment will I be prescribed?
That’s a clinical decision. Your clinician reviews your health information and your baseline blood test, then recommends what’s appropriate for you, if anything is.
What does the monthly price include?
Everything: the treatment, your blood tests (a baseline and a retest every 6 months), clinical reviews, support and delivery.
Can my treatment change over time?
Yes. Your clinician adjusts your dose as you progress, and can reassess your plan if a treatment isn’t right for you.
Do I need a blood test first?
Yes. The baseline blood test comes before any prescribing decision, so your clinician sees what’s going on inside before treatment starts.
See where you stand
The eligibility check takes a few minutes. Every plan starts with a blood test, so the decisions come from your numbers.
Get startedSources (1)
- Comparison table trial figures (main-analysis averages; separate trials): STEP UP doi.org/10.1016/S2213-8587(25)00226-8; SURMOUNT-1 doi.org/10.1056/NEJMoa2206038; OASIS 4 doi.org/10.1056/NEJMoa2500969; ATTAIN-1 doi.org/10.1056/NEJMoa2511774.
Numbered markers in the page text link to these entries. Trial figures are averages from separate trials, not a prediction for any one person.